← Retour à la une
Océanie · Marchés régionaux · Stockhead

Imagion Biosystems secures first site for MagSense Phase 1b/2 clinical trial

Publié par Stockhead · Australie il y a 49 min
Source: Imagion Biosystems
Source: Imagion Biosystems · Stockhead

Résumé détaillé

Imagion Biosystems has secured the first clinical trial site for its Phase 1b/2 trial of lead MagSense Imaging Agent in ... Read More The post Imagion Biosystems secures first…

Imagion has achieved a key milestone towards the start of its MagSense trial in HER2+ breast cancer. Pic: Getty Images

Special Report: Imagion Biosystems has secured the first clinical trial site for its Phase 1b/2 trial of lead MagSense Imaging Agent in HER2+ breast cancer after executing a clinical trial agreement (CTA) with US-based Regis Clinical Research.

The CTA marks a key milestone toward trial initiation for Imagion Biosystems (ASX:IBX), formally committing Regis to participation as a trial site.

Miami-based Regis is an independent clinical research organisation specialising in clinical trial management, with a focus on oncology.

Its team of investigators and researchers supports study initiation, trial conduct and patient recruitment.

Following execution of the CTA, Imagion and Regis intend to progress towards site activation and patient recruitment.

“We are excited to have Regis as our first trial site under contract,” said Imagion Biosystems, Inc. president Ward Detwiler.

“As an organisation focused on efficient study execution and with deep experience across oncology trials, Regis aligns with IBX’s focus on expediently advancing our clinical development goals.”

Beyond Regis, seven sites have been selected for the trial. IBX said it was working to finalise contracts and activate the remaining sites as quickly as possible.

Début de l'article, extrait de Stockhead. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur Stockhead Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (stockhead.com.au)

À lire aussi